Dear reader, in July 2026, the two companies that dominate the world's most valuable class of medicines went to court against each other, and the dispute is not about whether their drugs work. It is about the dose, and about who is allowed to describe a competitor to a television audience.

Novo Nordisk, the Danish maker of Ozempic and Wegovy, filed suit against Eli Lilly in federal court in New Jersey, alleging false advertising and unfair competition under the Lanham Act and state law. The target is two nationwide direct-to-consumer campaigns: Zepbound vs. Wegovy, and Mounjaro vs. Ozempic. Novo sued only after a formal cease-and-desist letter, which Lilly declined to act on. Novo's complaint is precise: the advertisements compare the highest approved doses of Lilly's medicines with lower doses of Novo's, drawing on trials that predate the regulator's approval of the newer, stronger doses now available.

One television spot places the two side by side and tells viewers that patients on Lilly's drug lost an average of 23 kilograms, compared with 15 on Novo's. The 15 is the 2.4-milligram dose of Wegovy from the 2024 SURMOUNT-5 trial. The dose Novo says was left out is the 7.2 milligram injection approved in March 2026, which, in the STEP UP trial, produced an average weight loss of 18.8 percent, about 21 kilograms. Novo says the omission is deliberate and that the campaigns have reached more than 700 million impressions since Lilly amended the advertisement following Novo's cease-and-desist letter in late April.

Lilly rejects this in equally direct terms. The stakes are not rhetorical: analysts expect the American obesity drug market alone to exceed a hundred billion dollars by 2030, and Novo has been losing ground in it. Its position is that the comparison rests on the only randomized, head-to-head weight-loss trial comparing the two molecules, and that Novo is asking a court to prevent it from communicating the results of a study it ran. Its advertising, it says, is truthful and transparent, and it intends to defend the case vigorously. Novo is seeking a permanent injunction that would pull the campaigns from every platform and compel a corrective advertising campaign, and has signaled it will move for a preliminary injunction if the ads do not come down voluntarily.

I have no interest in scoring this fight; a judge will decide it. What interests me is the pharmacology hiding inside the dispute, a lesson worth having, whatever the verdict.

Comparing two medicines properly requires a head-to-head trial giving both at doses equivalent in intent, usually the maximum tolerated dose of each, in the same patients under the same conditions. Anything short of that is an indirect comparison, and indirect comparisons are fragile. Trials run years apart recruit different patients, use different lifestyle programs, and define their endpoints differently. When you then match the top dose of one drug against a middling dose of the other, the resulting number tells you almost nothing about the molecules and a great deal about the arithmetic. This is not a subtle point. It is the first thing taught about comparative efficacy, and it is routinely lost between the trial report and the advertisement.

Which brings me to the part our region should take note of: Direct-to-consumer prescription drug advertising is legal in only two countries on earth, the United States and New Zealand. It is prohibited here, as across the Gulf, for reasons this case illustrates rather neatly: a patient watching a thirty-second comparison has no way to interrogate the dose, the trial, or the population. That is why the physician sits between the claim and the prescription.

But the prohibition is territorial, and the advertisement is not. These campaigns run on platforms that do not stop at borders and are amplified by influencers, weight-loss forums, and Arabic-language pharmacy accounts. The practical consequence in a Jeddah or Riyadh clinic is a patient who arrives already convinced, quoting a figure from an American commercial, asking for a specific brand by name and sometimes by dose. The regulation protects our airwaves and not our feeds.

A second consequence is quieter and more expensive. These medicines are largely paid for out of pocket here. A patient persuaded by a comparison based on mismatched doses may switch products, restart a titration schedule, experience another round of gastrointestinal side effects, and spend a great deal of money to arrive at a difference that, on the available trial evidence, may largely disappear at equivalent doses.

Dear reader, whichever way the New Jersey court rules, the useful conclusion is available now and belongs to the reader rather than the lawyers. In this class of medicine, the dose is not a footnote to the claim. It is the claim. Any comparison that does not state the doses of both drugs is not a comparison at all, and you are entitled to ask which numbers were left out.